ArticleFrontiers in oncology2025
Pathologic complete response after neoadjuvant therapy for locally advanced rectal cancer in a real-world setting: a population-based study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune-inflammatory indices as predictors of pathologic complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of observational studies.World journal of surgical oncology · 2026Pooled it
- Article
- Predicting Pathological Complete Response in Rectal Cancer: External Validation of Clinical Models.Cancers · 2026Article
- Efficacy and toxicity of neoadjuvant radiotherapy with concomitant dose escalation for rectal cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to determine the impact of time from neoadjuvant therapy (NAT) to surgery on the complete pathologic response (pCR) rate in patients with locally advanced rectal cancer. NAT decreases the local recurrence of rectal cancer. Some patients achieve a pCR. The optimal time between NAT and surgery to maximize pCR remains uncertain. Method: We identified adults with T Results: In total, 3,476 patients were included from between 2000 and 2017. Of these, 1,554 (44.7%) received LCRT and 1,796 (51.7%) SCRT. The pCR rate was 13.2% (181/1373) among the LCRT group and 1.5% (26/1770) among the SCRT group. A pCR among the SCRT group was positively associated with weeks from SCRT to surgery [odds ratio (OR) 1.45, 95% confidence interval (CI) 1.13,1.86; p=0.003], tumor grade (grade 1 OR 5.72, 95% CI 1.70, 19.30, p=0.005), and stage (stage 1 OR 7.07, 95% CI 2.49, 20.08, p=<0.001). The pCR rate among the LCRT group was not associated with weeks from LCRT to surgery but was associated with sex and stage. Median follow-up was 9.5 years, and median overall survival (OS) was 9.7 years. Among patients receiving LCRT, the 5-year OS rate was higher (69.8%) when surgery followed LCRT by 6-10 weeks compared to those undergoing surgery <6 weeks or 10+ weeks post-LCRT ( Conclusion: Among rectal cancers treated with LCRT in a population-based cohort, longer delay to radical resection is associated with increased pCR rate. However, the overall pCR rate was lower than that reported in trial populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.